It was the third trigger of the recession indicator in less than two weeks.Bondsread more
U.S. manufacturer growth slowed to the lowest in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
"My sense was we've added accommodation, and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Stocks traded higher on hopes the Fed chief will confirm expectations of easier monetary policy at a central banking summit this week.US Marketsread more
Apple plans to unveil three new iPhones in September, including two new "Pro" models and a successor to the iPhone XR, Bloomberg reported Thursday.Technologyread more
Former Prudent Bear Fund manager David Tice is urging investors to brace for a massive downturn.Trading Nationread more
Corporate profits posted modest growth in the second quarter as companies brace for slowing global growth.Retailread more
A Volkswagen spokesperson called the report that CEO Herbert Diess is interested in buying a stake in Tesla "completely unfounded."Technologyread more
A ruling against J&J could mean more big payouts in similar cases across the country.Health and Scienceread more
-executive@ (Adds executive quotes, background, PIX available)
NEW YORK, May 16 (Reuters) - Bayer AG is confident its appeals of recent court rulings that its glyphosate weed killer Roundup caused cancer will be successful, a senior executive said on Thursday, amid a steep selloff of the company's shares this week.
Liam Condon, president of Bayer's crop science division, said the appeals of jury rulings against the chemical will be heard by judges, a factor he sees as favorable to Bayer's chances.
A California jury on Monday awarded more than $2 billion to a couple who claimed Bayers glyphosate-based Roundup weed killer caused their cancer, in the largest U.S. jury verdict to date against the company in litigation over the chemical.
It was the third consecutive U.S. jury verdict against the company over the widely-used weed killer, which Bayer acquired as part of its $63 billion purchase of Monsanto last year.
"The key point is from a regulatory point of view, nothing has changed," Condon said at the BMO Farm to Market investor conference in New York. "We just need to get this litigation sorted out and move on."
Shares of Germany-based Bayer have fallen about 38 percent since the first adverse U.S. judgment on Roundup last August, leaving the company with a market value smaller than the price it paid for Monsanto.
The "phenomenal" selloff is due to investors being uncertain how to price the lawsuits into the stock, Condon said.
The experience has been in all industries (involved in litigation), these things always get solved, " he said. "There has been a significant overreaction there and its a great buying opportunity. Its almost like buy one, get one free. (Reporting by Rod Nickel in New York Editing by Bill Berkrot)